Last reviewed · How we verify

Carvedilol CR + Lisinopril — Competitive Intelligence Brief

Carvedilol CR + Lisinopril (Carvedilol CR + Lisinopril) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Beta-blocker + ACE inhibitor combination. Area: Cardiovascular.

phase 3 Beta-blocker + ACE inhibitor combination Beta-adrenergic receptors (β1, β2, α1) and Angiotensin-converting enzyme (ACE) Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Carvedilol CR + Lisinopril (Carvedilol CR + Lisinopril) — St. Paul Heart Clinic. Carvedilol CR (a non-selective beta-blocker with alpha-blocking activity) combined with Lisinopril (an ACE inhibitor) reduces blood pressure and cardiac workload through dual pathway inhibition.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Carvedilol CR + Lisinopril TARGET Carvedilol CR + Lisinopril St. Paul Heart Clinic phase 3 Beta-blocker + ACE inhibitor combination Beta-adrenergic receptors (β1, β2, α1) and Angiotensin-converting enzyme (ACE)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Beta-blocker + ACE inhibitor combination class)

  1. St. Paul Heart Clinic · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Carvedilol CR + Lisinopril — Competitive Intelligence Brief. https://druglandscape.com/ci/carvedilol-cr-lisinopril. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: